COVAXIN, India’s first vaccine candidate against novel coronavirus, developed by vaccine maker Bharat Biotech gets the approval of DCGI for Phase I and II clinical trials.
India’s first vaccine candidate against the novel coronavirus, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), has received approval from the Drug Controller General of India (DCGI) to conduct Phase I and 2 human trials. According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020.
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine has been developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India, the firm said in a release on Monday.
